Appili Therapeutics Updates on ATI-1701 Biodefense Vaccine at IDWeek 2024

Appili Therapeutics Inc., a company specializing in the development of drugs for infectious diseases and medical countermeasures, has announced participation in IDWeek 2024™, taking place from October 16-19, 2024, at the Los Angeles Convention Center. During this event, Gary Nabors, Ph.D., Chief Development Officer, along with Appili’s scientific team, will update attendees on the ATI-1701 vaccine candidate and present new efficacy data.

ATI-1701 is Appili's pioneering vaccine candidate designed to prevent tularemia, an infectious disease caused by the bacterium F. tularensis. This disease is highly infectious and can be aerosolized, making it a significant concern for biodefense. In preclinical studies, a single dose of ATI-1701 has shown to provide complete protection in animal models against lethal tularemia for up to one year following vaccination.

Appili has secured a significant financial commitment for the development of ATI-1701, receiving US$14M from the United States Air Force Academy, in collaboration with the Defense Threat Reduction Agency. These funds, as well as other potential funding sources, are expected to propel the ATI-1701 program towards an Investigational New Drug (IND) submission to the United States Food and Drug Administration (FDA) by 2025.

Dr. Gary Nabors expressed optimism about the progress: "The results from our 365-day vaccination and challenge study, alongside substantial funding commitments, greatly enhance ATI-1701’s advancement. This positions us well for an IND submission in 2025."

The specific details for the Appili presentation are as follows:
- Poster Title: "Toward the clinical development of ATI-1701, a genetically defined live attenuated tularemia vaccine"
- Date: October 17, 2024
- Time: 12:15 PM PT / 3:15 PM ET
- Location: Los Angeles Convention Center, Hall J & K

Appili's management team will also be available for in-person meetings throughout the conference to discuss their programs and future plans.

ATI-1701 is a novel, live-attenuated vaccine targeting F. tularensis. Tularemia is a Category A pathogen, notable for being highly infectious, more so than anthrax. Due to its ability to cause severe illness and its potential as a biological weapon, developing medical countermeasures for F. tularensis is a high priority for the United States and other global governments. Currently, no approved vaccine exists for tularemia in the United States or other major markets worldwide.

IDWeek 2024™ is organized by multiple societies, including the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), and others, focusing on the latest advancements in the prevention, diagnosis, and treatment of infectious diseases. This annual event showcases cutting-edge research and clinical practices to improve patient care across the lifespan.

Appili Therapeutics is dedicated to addressing life-threatening infections through its diversified portfolio of treatments. The company aims to identify urgent infectious diseases with unmet needs and develop novel therapies to save lives and improve health outcomes. Among their notable projects are an FDA-approved oral suspension of metronidazole for antimicrobial infections, a vaccine candidate to counter biological weapons, and a topical treatment for a disfiguring parasitic disease. Appili is led by a team with a proven track record in the fight against infectious diseases.